. Author manuscript; available in PMC: 2009 Oct 31.

Published in final edited form as: Can J Ophthalmol. 2009 Jun;44(3):e9–e12. doi: 10.3129/i09-061

Table 1.

Clinical characteristics, immunosuppressive medications, and adverse events in relation to infliximab treatment in scleritis patients

Patient	Age/gender	Time to quiescence^* (wk)	Concomitant ISM at baseline	Able to decrease other ISM (ISM at 26 wk, 48 wk)	Number of infliximab infusions	ISM grade (based on mg/kg dose)		Adverse events
Patient	Age/gender	Time to quiescence^* (wk)	Concomitant ISM at baseline	Able to decrease other ISM (ISM at 26 wk, 48 wk)	Number of infliximab infusions	Pre-infliximab	At 48 wk	Adverse events
1	43/Male	2	Prednisone 16mg	Yes (prednisone 2 mg, prednisone 2 mg)	11	2	1	None
2	28/Female	6	Prednisone 50 mg	Yes (prednisone 2.5, none)	11	5	0	None
3	21/Female	2	Prednisone 30 mg	Yes (none, none)	11	3	0	Ear infection with transient decreased hearing, UTI, lower RTI, and facial rash
4	55/Female	10	Prednisone 17.5 mg	Yes (prednisone 12.5, prednisone 10 mg)	12^†	2	1	UTI, diarrhea, upper RTI, nasal congestion and headache, mouth sores, head tremor, occasional numbness and tingling in extremities
5	34/Male	2	Prednisone 20 mg, Methotrexate 17.5 mg	No (failed after 26 wk; terminated)	8^‡	7	n/a	None

Primary outcome: quiescence in 14 wk.

^†

Escalated dose at week 34 visit.

^‡

Terminated from study (secondary to treatment failure) after week 26 visit.

Note: Prednisone expressed in daily doses. ISM, immunosuppressive medications; UTI, urinary tract infection; RTI, respiratory tract infection; n/a, not applicable.